In a pre-print study with The Lancet, the analysis workforce – from Oxford, Nanoro in Burkina Faso and the US – reported the trial outcomes of R21/Matrix-M, after testing a high and low dose of the vaccine in youngsters, between Might and August, earlier than peak malaria season.
